NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
Clinical Trials
50 trialsNCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
NCT04113018 2026-02-03
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT05497804 2026-02-03
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
Phase 2 Active not recruiting
NCT04430894 2026-01-29
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02969837 2026-01-16
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT05789303 2025-12-22
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
Phase 2 Recruiting
NCT04850599 2025-12-18
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03290950 2025-12-15
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02302495 2025-12-08
IFM2012-03
University Hospital, Lille
Phase 2 Completed
NCT04176718 2025-10-07
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT03500445 2025-10-03
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT03004287 2025-09-10
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT01559935 2025-09-08
CarBiRD
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT03314636 2025-08-08
CONPET
Oslo University Hospital
Phase 2 Active not recruiting
NCT01816971 2025-06-10
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT03556332 2025-04-29
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04263480 2025-04-04
CZAR-1
University of Ulm
Phase 2 Active not recruiting
NCT02405364 2025-01-27
IFM-CRd
University Hospital, Toulouse
Phase 2 Completed
NCT02203643 2024-12-05
FORTE
University of Turin, Italy
Phase 2 Active not recruiting
NCT04756401 2024-09-26
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03104842 2024-05-29
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
UniversitÀtsklinikum Hamburg-Eppendorf
Phase 2 Active not recruiting
NCT02891811 2024-03-29
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT03289299 2023-12-12
ASCENT
International Myeloma Foundation
Phase 2 Active not recruiting
NCT02318784 2023-12-05
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03224507 2023-11-24
MASTER
University of Alabama at Birmingham
Phase 2 Completed
NCT03673826 2023-11-01
HO147SMM
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT05909826 2023-06-18
KMM-KCd
Dong-A University Hospital
Phase 2 Not yet recruiting
NCT03891355 2022-09-15
FIL_KLIMT
Fondazione Italiana Linfomi - ETS
Phase 2 Unknown
NCT02415413 2022-09-10
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
PETHEMA Foundation
Phase 2 Active not recruiting
NCT03336073 2022-09-07
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
PETHEMA Foundation
Phase 2 Unknown
NCT05509374 2022-08-22
KMM2002
Samsung Medical Center
Phase 2 Unknown
NCT03256045 2022-05-09
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Terminated
NCT01813227 2022-04-13
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Hackensack Meridian Health
Phase 2 Completed
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT03606577 2021-04-28
IFM 2018-04
Nantes University Hospital
Phase 2 Active not recruiting
NCT02217163 2020-10-20
Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma
Singapore General Hospital
Phase 2 Completed
NCT01775930 2020-03-04
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03269552 2020-01-18
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
University of Washington
Phase 2 Terminated
NCT03815279 2019-08-16
iStopMM
Landspitali University Hospital
Phase 2 Enrolling by invitation
NCT02042950 2019-05-01
A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02047253 2018-12-19
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
University of Alabama at Birmingham
Phase 2 Completed
NCT01470196 2018-11-20
CaRD
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02572492 2018-08-17
CARFI
Aalborg University Hospital
Phase 2 Unknown
NCT01969565 2017-11-24
Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma
Emory University
Phase 2 Terminated
NCT01775553 2017-06-21
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01351623 2017-04-13
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01812720 2016-12-19
CARAMEL 2
Mayo Clinic
Phase 2 Withdrawn
NCT02020941 2016-11-02
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
Indiana University
Phase 2 Terminated
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn